FDA Drugs recall ·
Levothyroxine Sodium Tablets USP, 175 mcg, packaged in a) 90-count bottles… recall
- Recall number
- D-0121-2025
- Date
- (initiated November 18, 2024)
- Company / brand
- Viatris Inc
1000 Mylan Blvd, Canonsburg, PA, United States - Category
- Drugs › Class II
- Classification
- Class II
- Status
- Ongoing
- Units affected
- 19, 549 bottles
- Hazard tags
- Potency
- Initiated by
- Voluntary: Firm initiated
Read the official FDA notice ↗
Product
Levothyroxine Sodium Tablets USP, 175 mcg, packaged in a) 90-count bottles (NDC 0378-1817-77) and b) 1000-count bottles (NDC 0378-1817-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.
Why was it recalled?
Superpotent Drug and Subpotent Drug: potency failures obtained
What should you do?
FDA enforcement reports do not list a consumer remedy. Check the product codes below against what you have; if it matches, stop using it and follow the instructions in the firm's or FDA's official notice, or contact the company. If you have health concerns, contact your healthcare provider.
Product codes & lot numbers
Lot #: a) 3192915, 8172108, Exp. Date Mar 2025; b) 3208680, Exp. Date Sep 2025
Distribution
Nationwide within the United States and Puerto Rico
States: Puerto Rico
What does Class II mean?
Class II means use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or the probability of serious harm is remote.
Source: FDA (drugs), recall D-0121-2025. Official notice. Republished from public data; RecallFlag is not affiliated with the FDA.